EZH2 and leukocyte adhesion deficiency: Mechanistically, the molecular pathway TP73-AS1/miR-449a/enhancer of zeste homolog 2 (EZH2) promotes NSCLC tumorigenesis via epigenetic modulation, whereas TP73-AS1 promotes the progression of LAD through the activation of the PI3K/AKT signaling pathway [35,36].